CTOs on the Move

Cougar Biotechnology

www.cougarbiotechnology.com

 
Cougar Biotechnology is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Flo Health

Flo Health is a developer of Flo, the fastest growing AI-driven women`s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Apthera

Apthera, Inc. is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.